Piper Sandler Increases Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $30.00

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) had its price objective raised by Piper Sandler from $23.00 to $30.00 in a research note issued on Friday,Benzinga reports. The firm currently has an "overweight" rating on the stock. Piper Sandler's price target would indicate a potential upside of 36.57% from the stock's previous close.

A number of other brokerages have also recently weighed in on TEVA. StockNews.com cut Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, December 18th. Barclays increased their price target on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an "overweight" rating in a research report on Wednesday, December 18th. Finally, JPMorgan Chase & Co. raised their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a report on Monday, October 21st. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $22.13.

Teva Pharmaceutical Industries Stock Up 1.3 %

NYSE:TEVA traded up $0.29 during trading hours on Friday, reaching $21.97. The company's stock had a trading volume of 8,962,859 shares, compared to its average volume of 9,541,109. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The company has a market capitalization of $24.89 billion, a P/E ratio of -25.84, a price-to-earnings-growth ratio of 1.06 and a beta of 0.73. The stock has a 50 day moving average price of $19.24 and a two-hundred day moving average price of $18.20. Teva Pharmaceutical Industries has a 12 month low of $10.86 and a 12 month high of $22.80.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the firm's stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the transaction, the director now owns 695,000 shares of the company's stock, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the sale, the executive vice president now owns 44,104 shares of the company's stock, valued at $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Stifel Financial Corp boosted its position in Teva Pharmaceutical Industries by 54.0% in the third quarter. Stifel Financial Corp now owns 66,391 shares of the company's stock valued at $1,196,000 after buying an additional 23,283 shares during the last quarter. Thrivent Financial for Lutherans lifted its stake in Teva Pharmaceutical Industries by 21.8% during the 3rd quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company's stock valued at $4,046,000 after acquiring an additional 40,218 shares during the period. Sio Capital Management LLC acquired a new stake in Teva Pharmaceutical Industries during the 3rd quarter valued at approximately $24,314,000. CWA Asset Management Group LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $3,340,000. Finally, Two Sigma Advisers LP increased its stake in shares of Teva Pharmaceutical Industries by 15.3% in the third quarter. Two Sigma Advisers LP now owns 1,034,500 shares of the company's stock worth $18,642,000 after acquiring an additional 137,000 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.